Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
What are the differences between how AI systems handle JavaScript-rendered or interactively hidden content compared to ...
This is a summary of: Liu. H. et al. Viral RNA blocks circularization to evade host codon usage control. Nature https://doi.org/10.1038/s41586-025-09809-y (2025).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback